This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Agency for Science, Technology and Research, National University of Singapore. Active years: 2019.
Company Filing History:
1 out of 1,556 
1 out of 850 
Years Active: 2019
Title: Meihui Xu: Innovator in Dengue Antibody Research
Introduction
Meihui Xu is a prominent inventor based in Singapore, known for his significant contributions to the field of dengue virus research. His innovative work has led to the development of a patent that addresses critical challenges in dengue treatment and prevention.
Latest Patents
Meihui Xu holds a patent titled "Serotype cross-reactive, dengue neutralizing antibody and uses thereof." This patent discloses isolated antibodies, or antigen binding fragments, that bind to dengue virus epitopes. The invention includes kits, compositions, and passive vaccines that utilize these antibodies. Notably, the antibody or antigen binding fragment is capable of binding to a whole dengue virus particle more effectively than to a dengue virus surface glycoprotein. The patent also outlines methods for using these antibodies, including nucleic acids encoding them, vectors expressing the nucleic acids, and methods of manufacturing them.
Career Highlights
Throughout his career, Meihui Xu has worked with esteemed institutions such as the Agency for Science, Technology and Research and the National University of Singapore. His research has significantly advanced the understanding of dengue virus interactions and potential therapeutic approaches.
Collaborations
Meihui Xu has collaborated with notable colleagues, including Cheng-I Wang and Katja Fink, who have contributed to his research endeavors.
Conclusion
Meihui Xu's innovative work in dengue antibody research exemplifies the impact of scientific inquiry on public health. His contributions continue to pave the way for advancements in the treatment and prevention of dengue virus infections.